AC Immune to Acquire Parkinson’s Disease Vaccine Candidate

 

AC Immune - Figure 1

All stock acquisition & PIPE maintains and enhances AC Immune's strong cash position.

All stock acquisition & PIPE maintains and enhances AC Immune's strong cash position.

Figure 2

ACIU moves to the forefront of Parkinson's drug development

ACIU moves to the forefront of Parkinson's drug development

All-stock transaction maintains AC Immune’s strong cash position

USD 25 million private placement led by premier investor Athos Service GmbH

Transactions expand and accelerate AC Immune’s therapeutic development in Parkinson’s disease

AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson’s disease

Conference call scheduled today at 8:30 am ET / 2:30 pm CET

Conference Call Information
AC Immune will hold a conference call today, July 27, 2021, at 8:30 am ET / 2:30 pm CET. Interested participants and investors may access the conference call by dialing:

• 877-407-0792 (U.S.)

• +1 201-689-8263 (International)

• Conference ID: 13721912
  

A live webcast will be accessible via the Events section of the Company’s website. An archive of the webcast will be available for 90 days beginning at approximately 9:30 am ET / 3:30 pm CET, today, July 27, 2021.

https://finance.yahoo.com/news/ac-immune-announces-strategic-acquisition-113000880.html